As our study provided a proof-in-concept of dual targeting the overlapping and non-overlapping actions IL-36R and IL-17A in preclinical studies (Figure 6), with a focusing on skin inflammation, we anticipate that dual blockade of IL-17A and IL-36R have potentials in many other inflammatory/fibrotic diseases with the involvement of these two inflammatory cytokines. Here, IL17A is linked to dermatitis.